Aligos Therapeutics (ALGS) Competitors $8.50 -0.19 (-2.19%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.46 -0.04 (-0.41%) As of 07/15/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALGS vs. OGI, NLTX, PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, and TLSAShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Organigram Global (OGI), Neoleukin Therapeutics (NLTX), ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Its Competitors Organigram Global Neoleukin Therapeutics ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences Organigram Global (NASDAQ:OGI) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Do institutionals & insiders hold more shares of OGI or ALGS? 34.6% of Organigram Global shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is OGI or ALGS more profitable? Organigram Global has a net margin of 8.05% compared to Aligos Therapeutics' net margin of -1,628.75%. Aligos Therapeutics' return on equity of 14.67% beat Organigram Global's return on equity.Company Net Margins Return on Equity Return on Assets Organigram Global8.05% -5.93% -4.39% Aligos Therapeutics -1,628.75%14.67%7.19% Do analysts recommend OGI or ALGS? Aligos Therapeutics has a consensus price target of $70.00, suggesting a potential upside of 723.53%. Given Aligos Therapeutics' higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Organigram Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OGI or ALGS? In the previous week, Organigram Global had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 3 mentions for Organigram Global and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat Organigram Global's score of 0.64 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organigram Global 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, OGI or ALGS? Organigram Global has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Which has preferable valuation and earnings, OGI or ALGS? Organigram Global has higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganigram Global$117.47M1.63-$33.39M$0.1014.30Aligos Therapeutics$3.94M13.18-$131.21M-$17.51-0.49 SummaryAligos Therapeutics beats Organigram Global on 8 of the 14 factors compared between the two stocks. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.13M$2.96B$5.61B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.4920.2228.5219.58Price / Sales13.18290.74426.1793.37Price / CashN/A43.1536.0257.93Price / Book-1.137.568.135.54Net Income-$131.21M-$55.11M$3.24B$257.73M7 Day Performance-1.85%3.81%0.20%-0.08%1 Month Performance5.59%11.60%5.98%8.09%1 Year Performance-35.34%-2.11%26.15%13.02% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics4.1494 of 5 stars$8.50-2.2%$70.00+723.5%-33.3%$53.13M$3.94M-0.4990OGIOrganigram Global1.1396 of 5 stars$1.39-2.8%N/A-16.4%$191.53M$117.47M13.90860News CoverageNLTXNeoleukin TherapeuticsN/A$20.09+1.7%N/A-47.7%$188.81MN/A-6.4690PROKProKidney3.5224 of 5 stars$0.61-4.8%$3.50+477.1%+41.0%$186.51M$306K-1.013Trending NewsAnalyst ForecastGap UpALMSAlumis3.4542 of 5 stars$3.31-2.6%$22.86+590.5%-69.1%$184.98MN/A0.00N/APositive NewsELDNEledon Pharmaceuticals1.8256 of 5 stars$3.11+1.0%$9.00+189.4%+47.5%$184.44MN/A-1.4810Analyst RevisionCYBNCybin2.4763 of 5 stars$7.87-0.9%$86.00+992.8%N/A$181.20MN/A-1.8050TILInstil Bio3.4142 of 5 stars$23.64-14.0%$119.00+403.4%+76.7%$180.37MN/A-1.97410Positive NewsHigh Trading VolumePBYIPuma Biotechnology4.1989 of 5 stars$3.54-1.1%$7.00+97.7%-5.5%$177.68M$230.50M4.60200Gap UpVYGRVoyager Therapeutics3.8932 of 5 stars$3.04-5.0%$13.39+340.5%-65.6%$177.08M$80M-2.08100TLSATiziana Life Sciences1.1687 of 5 stars$1.53+1.3%N/A+82.6%$176.44MN/A0.008 Related Companies and Tools Related Companies Organigram Global Competitors Neoleukin Therapeutics Competitors ProKidney Competitors Alumis Competitors Eledon Pharmaceuticals Competitors Cybin Competitors Instil Bio Competitors Puma Biotechnology Competitors Voyager Therapeutics Competitors Tiziana Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALGS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts